Imugene Limited (IMU.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
At close: 04:10PM AEST
| Previous close | 0.0550 |
| Open | 0.0560 |
| Bid | 0.0550 x 0 |
| Ask | 0.0560 x 0 |
| Day's range | 0.0550 - 0.0570 |
| 52-week range | 0.0390 - 0.1500 |
| Volume | |
| Avg. volume | 20,446,420 |
| Market cap | 411.571M |
| Beta (5Y monthly) | 3.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings date | 23 Aug 2024 - 27 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.35 |
Simply Wall St.Is Imugene (ASX:IMU) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- Simply Wall St.
Those who invested in Imugene (ASX:IMU) five years ago are up 361%
For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly...
GlobeNewswireBile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort
The expansion trial is expected to enrol 10 patients with bile tract cancers (cholangiocarcinoma)Interim results from the MAST trial have demonstrated positive responses in gastrointestinal cancers, particularly in cholangiocarcinoma where one patient treated with CF33-hNIS (VAXINIA) achieved a complete response and another patient achieved stable diseaseThe fifth cohort in the intratumoural (IT) arm of the VAXINIA monotherapy trial has now been cleared with no safety signals seen to date; the c
© 2024 Yahoo. All rights reserved.